Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

ABSTRACT:

Background

Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR-T790M mutation (T790M). We sought to describe T790M changes in serum/plasma during osimertinib therapy and correlate these changes with treatment outcomes.

Material and methods

Serum/plasma from EGFR-mutant lung cancer patients with T790M-AR was collected before and during osimertinib treatment. Changes in T790M were evaluated using a peptide-nucleic acid-PCR assay, and correlated with clinical and radiographic response.

Results

Thirteen patients were included. Median time on osimertinib treatment was 10.6 months with a median progression-free survival of 13

SUBMITTER: Moran T 

PROVIDER: S-EPMC6007479 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature